Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 1044

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 7
Chunk 1044
---
 diverse portfolio of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly
    by program progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel which mitigates
    business risk.

    ●
    Providing
    attractive economic upside to our partners at research universities and medical centers. We have a structure wherein our parent company
    houses each program in a subsidiary. We believe this structure is optimal to provide attractive economic incentives to the discovering
    institution and its researchers.

    ●
    Employing
    a multi-disciplinary approach to drug discovery and development across our programs. Our business model is based on bringing together
    the appropriate disciplines and expertise needed for each of our programs and leveraging learnings across programs and disease areas.

    ●
    Exploiting
    multiple commercialization options to maximize each program’s value. Throughout the development of our product candidates,
    we plan to continually assess that program’s potential paths to market, and we will endeavor to identify and maximize commercial
    value through various options, including internal advancement, partnerships with established companies, and spin-outs or IPOs.

    ●
    Leadership
    team comprised of academic, scientific and business innovators. We have assembled an industry-leading, multi-disciplinary team consisting
    of physicians, scientists and business leaders with significant experience in progressing product candidates from early-stage research
    through clinical trials, regulatory approval and ultimately to commercialization. Although our company has not yet developed or commercialized
    any biopharmaceutical products, key members of our management team have experience doing so in previous endeavors.

We
believe our differentiated business model will enable us to commercialize our products, if approved, and will allow us to replicate our
licensing partnerships through aligned incentive structures with research universities and medical centers.

Our
pipeline consists of both preclinical and clinical-stage programs. We anticipate moving certain preclinical product candidates in our
oncology, fibrosis and/or infectious disease programs into the clinic in the next 12 to 24 months.

On
December 31, 2020, we executed a Development and Manufacturing Services Agreement with Lonza AG and affiliate Lonza Sales AG (“Lonza”).
We engaged Lonza (and Lonza affiliates) for the development and manufacture of certain products and services along with assistance in
developing the product OCX-253. Under this agreement, Lonza will perform the following key activities in two stages in support of our
IND-enabling program